Accepted Manuscript



Title: Interpretation of clinical endpoints in trials of acute myeloid leukemia

Author: Bruno C. Medeiros

PII: S0145-2126(18)30030-4
DOI: https://doi.org/10.1016/j.leukres.2018.02.002
Reference: LR 5910

To appear in: *Leukemia Research*

Received date: 10-10-2017
Revised date: 26-1-2018
Accepted date: 5-2-2018

Please cite this article as: Medeiros Bruno C.Interpretation of clinical endpoints in trials of acute myeloid leukemia.*Leukemia Research* https://doi.org/10.1016/j.leukres.2018.02.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

LR-D-17-00352
Revised submission

Interpretation of clinical endpoints in trials of acute myeloid leukemia

Running title: Endpoints in AML clinical trials

Bruno C. Medeiros, MD

Affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Corresponding author:

Bruno C. Medeiros

Stanford University

875 Blake Wilbur Dr

Stanford, CA, USA 94305-5821

Email: brunom@stanford.edu

Fax: 650-498-6000

Phone: 650-724-5203

Highlights:

- Internal (eg, design) and external (eg, SCT) factors affect endpoint interpretation (*85 characters including spaces*)
- OS is the gold standard in AML endpoints, but other endpoints are gaining ground (*82 characters including spaces*)
- Time-to-event endpoints are often interpreted using the HR and associated *P* values (*84 characters including spaces*)

Download English Version:

https://daneshyari.com/en/article/8453332

Download Persian Version:

https://daneshyari.com/article/8453332

Daneshyari.com